Drug Discovery Informatics Market to 2031 - Growth and Trends

Drug Discovery Informatics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Workflow (Discovery Informatics and Drug Development), Service (Sequence Analysis Platform, Molecular Modeling, Clinical Trial Data Management, Docking, and Others), Solution (Software and Services), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

  • Report Code : TIPHE100000965
  • Category : Healthcare IT
  • No. of Pages : 150

Drug Discovery Informatics Market to 2031 - Growth and Trends

Buy Now

[Research Report] The drug discovery informatics market was valued at US$ 3.07 billion in 2023 and is expected to reach US$ 8.17 billion by 2031; it is estimated to record a CAGR of 13.0% during 2023–2031.

Market Insights and Analyst View:

The drug discovery informatics  market forecast is derived on the basis of findings from various secondary and primary research sources.

Drug discovery informatics is a field that integrates computational and information sciences with chemistry and biology. It uses various computational tools, algorithms, and databases to study and interpret vast volumes of biological and chemical data. By utilizing the power of informatics, researchers can speed up the drug discovery process, resulting in the identification of potential drug candidates more efficiently and cost-effectively. Thus, the adoption of informatics tools is contributing to the growing drug discovery informatics market size.

Drivers Affecting Drug Discovery Informatics Market Growth

Pharmaceutical and biopharmaceutical industries invest heavily in R&D to develop new products and expand product pipelines in areas such as immunology, cancer, and infectious diseases. For instance, many innovative pharmaceutical companies are now investing in genomics to re-energize drug discovery. According to the article published by the Journal of Precision Medicine in March 2021, AstraZeneca launched a project to sequence 2 million genomes—a massive initiative aimed at collecting genome sequences and health records over the next decade. The same source further stated that GlaxoSmithKline invested £40 (UD$ 42.48) million to expand its partnership with the UK Biobank. This investment supports the sequencing of 500,000 individuals, generating a uniquely rich data resource that is both anonymized and secure. Instead of sourcing data, the leading pharmaceutical companies are tapping into population data sets that are rich in genomic, phenotypic, and clinical data. Therefore, the increasing investments in activities focused on drug discovery are driving the drug discovery informatics market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Drug Discovery Informatics Market: Strategic Insights

Drug Discovery Informatics Market
  • CAGR
    CAGR (2023 - 2031)
    13.0%
  • Market Size 2023
    US$ 3.07 Billion
  • Market Size 2031
    US$ 8.17 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Certara
  • Infosys Ltd
  • Collaborative Drug Discovery Inc
  • Jubliant Biosys
  • Curia Global Inc
  • Chemaxon Ltd
  • Charles River Laboratories
  • Agilent Technologies Inc
  • Illumina Inc

Regional Overview

Regional Overview
  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Market SegmentWorkflow
  • Discovery Informatics and Drug Development
Market SegmentService
  • Sequence Analysis Platform
  • Molecular Modeling
  • Clinical Trial Data Management
  • Docking
  • Others
Market SegmentSolution
  • Software and Services
Market SegmentEnd User
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Others
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Report Segmentation and Scope:

The "Global Drug Discovery Informatics Market Analysis to 2031" is a specialized and in-depth study focusing on the global market dynamics to help identify the key driving factors, future trends, and lucrative opportunities that would, in turn, aid in identifying major revenue pockets. The report aims to provide an overview of the market with detailed market segmentation by workflow, services, solutions, and end user. The scope of the drug discovery informatics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

By workflow, the market is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023. The drug development segment is projected to register a higher CAGR from 2023 to 2031.

The market, by service, is segmented into sequence analysis platforms, molecular modeling, clinical trial data management, docking, and others. The sequence analysis platform segment is anticipated to hold the largest drug discovery informatics market share in 2023. The molecular modeling segment is projected to register the highest CAGR from 2023 to 2031.

By solution, the drug discovery informatics market is segmented into software and services. The services segment held a larger market share in 2023, and the same segment is projected to register a higher CAGR from 2023 to 2031.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2023. The contract research organizations segment is expected to register the highest CAGR from 2023 to 2031.

Regional Outlook:

North America held the largest drug discovery informatics market share in 2023. The US held the largest share of the market in 2023, followed by Canada. This is attributed to factors such as the presence of major players, including Charles River Laboratories, Certara, and Curia, the high incidence of infectious diseases, and the rapid adoption of new and advanced R&D tools by leading pharmaceutical companies and Contract Research Organizations (CROs) for drug discovery and development. These companies are increasingly focusing on joint ventures and research collaborations, which are further expected to boost market growth in the region. For instance, in August 2022, Atomwise entered into a strategic multi-target research collaboration with Sanofi for AI-powered drug discovery. The collaboration will focus on leveraging the company's AtomNet platform for up to five drug targets as part of their computational discovery and research efforts.

Drug Discovery Informatics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 3.07 Billion
Market Size by 2031 US$ 8.17 Billion
Global CAGR (2023 - 2031) 13.0%
Historical Data 2021-2023
Forecast period 2023-2031
Segments Covered By Workflow
  • Discovery Informatics and Drug Development
By Service
  • Sequence Analysis Platform
  • Molecular Modeling
  • Clinical Trial Data Management
  • Docking
  • Others
By Solution
  • Software and Services
By End User
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Others
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Certara
  • Infosys Ltd
  • Collaborative Drug Discovery Inc
  • Jubliant Biosys
  • Curia Global Inc
  • Chemaxon Ltd
  • Charles River Laboratories
  • Agilent Technologies Inc
  • Illumina Inc
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Industry Developments and Future Opportunities:

As per company press releases, a few initiatives taken by key players operating in the global drug discovery informatics market are listed below:

  • In January 2024, Evotec partnered with the Crohn's & Colitis Foundation to develop new treatments for inflammatory bowel disease (IBD). Under this partnership, both companies will use Evotec's comprehensive R&D platform to advance drug discovery for two innovative drug targets that address fibrosis and impaired intestinal barrier function.
  • In November 2023, Certara introduced Simcyp Biopharmaceutics software, which aims to increase the efficiency of formulation development for new and generic drugs. The Simcyp Biopharmaceutics software is designed to assist biopharmaceutics, formulation, and scientists in quickly and cost-effectively formulating complex, novel, and generic small molecule medicines.
  • In June 2022, Chemical.AI and Chemaxon announced a collaboration to integrate their scientific informatics software. Chemical.AI, a renowned Artificial Intelligence (AI) firm, announced a strategic partnership with Chemaxon, a leading chemical and biological software development company. The collaboration allows end users to access Chemaxon's Design Hub and Chemical.AI's ChemAIRS as an option.
  • In April 2022, Certara, Inc. and Chemaxon entered a strategic partnership to modernize pharmaceutical research. The partnership provides interconnectivity between their scientific informatics workflows. Certara's Scientific Informatics software will seamlessly connect with Chemaxon's Design Hub, providing users with analytics and compound design. This co-development builds on integrations between Certara and Chemaxon products, such as the JChem chemistry cartridge, MarvinSketch, and JChem for Office.

Competitive Landscape and Key Companies:

Certara; Infosys Ltd.; Collaborative Drug Discovery, Inc.; Jubliant Biosys; Curia Global, Inc.; Chemaxon Ltd; Charles River Laboratories; Agilent Technologies, Inc.; Illumina, Inc; Boehringer Ingelheim International GmbH; and Evotec are among the prominent companies profiled in drug discovery informatics market report. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.

Report Coverage

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

Segment Covered

Workflow, Service, Solution, End User, and Geography

Regional Scope

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is drug discovery informatics?

Drug discovery informatics is a field that integrates computational and information sciences with chemistry and biology. It uses various computational tools, algorithms, and databases to study and interpret vast volumes of biological and chemical data.

Who are the major players in the drug discovery informatics?

The drug discovery informatics majorly consists of the players, including Certara; Infosys Ltd.; Collaborative Drug Discovery, Inc.; Jubliant Biosys; Curia Global, Inc.; Chemaxon Ltd; Charles River Laboratories; Agilent Technologies, Inc.; Illumina, Inc; Boehringer Ingelheim International GmbH; and Evotec.

What factors drive the drug discovery informatics?

Key factors driving the drug discovery informatics growth are the increasing investments in the R&D of new drug molecules by pharmaceutical companies and the growing adoption of computational and information tools for drug discovery and development.

Which type segment dominates the drug discovery informatics?

The drug discovery informatics market, by workflow, is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023.

What was the estimated drug discovery informatics size in 2023?

The drug discovery informatics was valued at US$ 3.073billion in 2023.

What are the growth estimates for the drug discovery informatics till 2031?

The drug discovery informatics is expected to be valued at US$ 8.17 billion in 2031.

The List of Companies - Drug Discovery Informatics Market

  1. Certara
  2.  Infosys Ltd.
  3.  Collaborative Drug Discovery, Inc.
  4.  Jubliant Biosys
  5. Curia Global, Inc.
  6. Chemaxon Ltd
  7. Charles River Laboratories
  8. Agilent Technologies, Inc.
  9. Illumina, Inc
  10. Boehringer Ingelheim International GmbH

Trends and growth analysis reports related to Healthcare IT : READ MORE..